Bruker Declares Quarterly Cash Dividends on Common and Preferred Shares
BILLERICA, Mass., (BUSINESS WIRE) – Bruker Corporation (Nasdaq: BRKR, BRKRP), a global leader in scientific instruments, analytical and diagnostic solutions, today announced that its Board of Directors (“Board”) has approved the declaration and payment of regular quarterly cash dividends on both the company’s common stock and its 6.375% Mandatory Convertible Preferred Stock, Series A. The decision underscores Bruker’s continued commitment to delivering value to its shareholders through consistent returns and disciplined financial management.
Details of the Common Stock Dividend
The Board of Directors approved a quarterly cash dividend of $0.05 per share on Bruker’s common stock, par value $0.01 per share (the “Common Stock Dividend”). This dividend will be payable on January 2, 2026, to shareholders of record as of the close of business on December 8, 2025.
This quarterly distribution continues in established dividend policy, reflecting the company’s financial strength, stable cash flows, and confidence in its long-term growth strategy. the common stockholders have historically benefited from the company’s ability to generate strong operating cash flows, enabling it to reinvest in innovation while also providing consistent shareholder returns through dividends and share repurchases.
Details of the Preferred Stock Dividend
In addition to the common stock dividend, the Board of Directors has also declared a quarterly cash dividend of $3.6745 per share on Bruker’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The preferred stock dividend will be payable on December 1, 2025, to holders of record as of the close of business on November 15, 2025.
The dividend rate of 6.375% on the Mandatory Convertible Preferred Stock remains unchanged and continues to offer a fixed, reliable income stream for investors holding these securities. The preferred shares, which carry both equity and income characteristics, are typically converted into shares of common stock upon maturity or under specified terms outlined at issuance.
Commitment to Shareholder Value and Financial Discipline
The declaration of these dividends demonstrates on continued focus on maintaining a balanced capital allocation strategy—one that supports sustainable growth while returning capital to shareholders. The company’s ongoing profitability, operational resilience, and conservative balance sheet management have enabled Bruker to pursue growth initiatives while still delivering consistent cash returns.
“Our Board’s decision to declare these quarterly dividends reaffirms Bruker’s strong financial position and our ongoing commitment to delivering long-term value to our shareholders,” said Frank H. Laukien, Ph.D., President and Chief Executive Officer of Bruker Corporation. “Bruker’s performance continues to be supported by robust demand for our scientific instruments, analytical systems, and solutions that drive progress in life science, materials research, and applied markets. The ability to sustain regular dividends reflects the underlying strength and predictability of our business model.”
Strategic Overview: Sustaining Growth Through Innovation
Founded in 1960, Bruker has built a reputation as a trusted partner to academic institutions, government laboratories, and industrial organizations around the world. The company’s diverse portfolio of products and solutions spans multiple scientific and technological fields, including nuclear magnetic resonance (NMR), mass spectrometry, X-ray diffraction, and optical and infrared spectroscopy. In recent years, Bruker has also expanded into life science tools, molecular diagnostics, and proteomics research technologies.
Bruker’s commitment to innovation continues to fuel its long-term growth strategy. The company regularly reinvests a significant portion of its operating income into research and development (R&D) to enhance its technology platforms and maintain leadership in precision measurement and life science instrumentation. This dedication to R&D not only strengthens the company’s competitive position but also supports the consistent financial performance that enables regular dividend distributions.
Dividend Policy and Outlook
Bruker’s dividend policy is designed to provide a predictable and stable return of capital to shareholders while maintaining financial flexibility to pursue strategic investments, acquisitions, and technological advancements. The $0.05 per share quarterly common stock dividend translates to an annualized rate of $0.20 per share, which reflects a moderate payout ratio aligned with the company’s growth-oriented investment approach.
The quarterly preferred stock dividend, based on a 6.375% annual rate, continues to provide an attractive fixed income alternative for investors seeking stable returns within Bruker’s capital structure. The preferred shares were originally issued to strengthen the company’s equity base and provide additional capital for strategic initiatives while offering investors a defined dividend yield until conversion.
The continuation of these dividends suggests confidence in Bruker’s operating outlook for fiscal 2026 and beyond. The company has previously guided toward sustained revenue growth, margin expansion through operational efficiency, and continued investment in high-value market segments such as biopharma, advanced materials, and next-generation molecular diagnostics.
Financial Strength and Capital Allocation
As of the most recent reporting period, Bruker maintained a strong balance sheet with ample liquidity and a disciplined approach to capital management. The company’s ability to consistently generate free cash flow supports both ongoing business investments and shareholder returns.
Bruker’s capital allocation priorities remain centered around three key objectives:
- Investing for Growth – Continued funding of R&D initiatives, digital transformation projects, and expansion into high-growth life sciences and biopharma markets.
- Maintaining Financial Flexibility – Prudent management of debt and liquidity to ensure resilience amid changing macroeconomic conditions.
- Returning Value to Shareholders – Sustaining dividend payments and pursuing share repurchases when appropriate.
This balanced approach allows Bruker to preserve long-term strategic flexibility while ensuring that shareholders benefit from the company’s financial success.
About Bruker Corporation – Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics
source Link: https://www.businesswire.com
